[Age-related macular degeneration and glaucoma: intraocular pressure monitoring after intravitreal injections].
In recent decades the problem of low vision and blindness in elderly people became major and socially significant issue. The number of patients having age-related macular degeneration (AMD) in association with glaucoma grows all over the world that attaches medical and social value to this problem. 102 patients with AMD were under follow-up, 7 of them had primary open-angle glaucoma (POAG). Three consecutive injections of ranibizumab resulted in visual acuity increase from 0.21 +/- 0.17 till 0.37 +/- 0.12. The mean retinal thickness in foveal zone decreased from 289.36 +/- 88.73 till 230.47 +/- 88.02 microm. Ocular hypertension within 12 hours after procedure was observed in 13 (12.7%) of 102 patients. In all cases intraocular pressure (IOP) returned to preoperative values in 3 days after hypotensive medical treatment. In one case trabeculectomy was performed simultaneously with ranibizumab intravitreal injection, the next two injections were performed in a month intervals. So the problem of IOP increase after intravitreal injections remains unsolved. Glaucoma is not an absolute contraindication to intravitreal injections in treatment of exudative AMD although patients with associated conditions need individual approach in terms of both IOP compensation and number of ranibizumab injections.
S E
SE
Avetisov
V P
VP
Erichev
M V
MV
Budzinskaia
M A
MA
Karpilova
I V
IV
Gurova
I V
IV
Shchegoleva
E A
EA
Chikun
D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D005901:Glaucoma / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects / Q000502:physiology*; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods*; D000069579:Ranibizumab; D012160:Retina / Q000473:pathology; D014065:Tonometry, Ocular / Q000379:methods*
D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab